Annual report pursuant to Section 13 and 15(d)

Going Concern (Details Narrative)

v3.23.1
Going Concern (Details Narrative) - USD ($)
 3 Months Ended 12 Months Ended
Jan. 01, 2023
Aug. 31, 2022
Jun. 20, 2022
Jun. 09, 2022
Jun. 08, 2022
Jun. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Mar. 27, 2023
Mar. 17, 2023
May 05, 2022
Oct. 31, 2021
Oct. 29, 2021
Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Cost of product             $ 13,607,000 $ 14,314,000            
NRV adjustment amount           $ 700,000                
Sale of business units   $ 6,200,000                        
Earnout payment   1,043,000                        
Operating loss             (3,617,000) (6,336,000)            
Cash, cash equivalents and restricted cash             4,828,000 3,314,000           $ 3,372,000
Total current assets             12,154,000 12,166,000            
Current liabilities             14,283,000 15,682,000            
Line of credit             $ 1,500,000            
Loan Agreement [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Line of credit                 $ 1,500,000          
Management [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Operating loss             3,600,000              
Cash, cash equivalents and restricted cash             4,800,000              
Total current assets             12,200,000              
Current liabilities             $ 14,300,000              
Pharma Solutions [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Sale of business units   $ 6,560,000                        
Subsequent Event [Member] | Management [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Cash                   $ 5,700,000        
Thy Ge NEXT [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Cost of product     $ 806 $ 806 $ 2,919                  
Thy Ge NEXT [Member] | Subsequent Event [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Cost of product $ 1,266                          
Term Loan [Member] | Broad Oak [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Term loan                       $ 8,000,000.0 $ 8,000,000  
Term Loan [Member] | Broad Oak [Member] | Convertible Debt [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Term loan                     $ 2,000,000.0      
Revolving Credit Facility [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Line of crerdit maximum borrowing capacity                       $ 7,500,000